Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

HR-positive, HER2-negative Advanced Breast Cancer

Tundra lists 3 HR-positive, HER2-negative Advanced Breast Cancer clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT06625775

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.

Gender: All

Ages: 18 Years - Any

Updated: 2026-04-02

18 states

Solid Tumor, Adult
Metastatic Breast Cancer
Advanced Breast Cancer
+8
RECRUITING

NCT06950086

Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors

This study is to evaluate the safety, pharmacokinetics, and preliminary antitumor activity of TYK-00540 as monotherapy or combined with fulvestrant in advanced solid tumors.

Gender: All

Ages: 18 Years - Any

Updated: 2025-04-29

1 state

HR-positive, HER2-negative Advanced Breast Cancer
RECRUITING

NCT06805812

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

PALMARES-2 is a retrospective/prospective, observational, multicenter, population-based study, aiming at providing real-world evidences on HR+/HER2- aBC patients treated with first-line CDK4/6i plus ET. The present study has the objective to collect data coming from different sources, i.e. RWD, medical images and biological samples, from patients treated with CDK4/6i as first-line of therapy for HR+/HER2- aBC. In consideration of the complexity of data collected and different objectives of the study, this master protocol foresees different sub-studies, which encompasses different methodologies for data collection, data extraction and analyses.

Gender: All

Ages: 18 Years - Any

Updated: 2025-02-03

Breast Adenocarcinoma
Breast Cancer Stage IV
Breast Cancer, Metastatic
+38